Recent Updates — CLNN

Clene Inc. entered into a securities purchase agreement on September 15, 2026, to issue and sell 1,219,513 shares of common stock at $3.28 per share in a registered direct offering led by Chairman David Matlin and founding investor Kensington Capital Holdings. The transaction generates approximately $4 million in gross proceeds with an expected closing date of September 17, 2026. Clene intends to use the net proceeds alongside existing cash to fund general corporate purposes, including regulatory dialogue, New Drug Application preparation for its lead candidate CNM-Au8, expanded access protocols, and manufacturing expansion. The company is a clinical-stage biotechnology firm focused on developing therapies for neurodegenerative diseases such as ALS.